On January 24, 2024, the IND for ZHB103 Injection, a central nervous system drug originally developed by ZONHONBIO with fully independent intellectual property rights at home and abroad, was formally approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute ischemic stroke.